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Abstract
Background:  The emergence and spread of Plasmodium falciparum resistance to almost all
available antimalarial drugs necessitates the search for new chemotherapeutic compounds. The
ubiquitin/proteasome system plays a major role in overall protein turnover, especially in fast
dividing eukaryotic cells including plasmodia. Previous studies show that the 20S proteasome is
expressed and catalytically active in plasmodia and treatment with proteasome inhibitors arrests
parasite growth. This is the first comprehensive screening of proteasome inhibitors with different
chemical modes of action against laboratory strains of P. falciparum. Subsequently, a selection of
inhibitors was tested in field isolates from Lambaréné, Gabon.
Methods: Epoxomicin, YU101, YU102, MG132, MG115, Z-L3-VS, Ada-Ahx3-L3-VS, lactacystin,
bortezomib (Velcade®), gliotoxin, PR11 and PR39 were tested and compared to chloroquine- and
artesunate-activities  in a standardized in vitro drug susceptibility assay against P. falciparum
laboratory strains 3D7, D10 and Dd2. Freshly obtained field isolates from Lambaréné, Gabon, were
used to measure the activity of chloroquine, artesunate, epoxomicin, MG132, lactacystin and
bortezomib. Parasite growth was detected through histidine-rich protein 2 (HRP2) production.
Raw data were fitted by a four-parameter logistic model and individual inhibitory concentrations
(50%, 90%, and 99%) were calculated.
Results: Amongst all proteasome inhibitors tested, epoxomicin showed the highest activity in
chloroquine-susceptible (IC50: 6.8 nM [3D7], 1.7 nM [D10]) and in chloroquine-resistant
laboratory strains (IC50: 10.4 nM [Dd2]) as well as in field isolates (IC50: 8.5 nM). The comparator
drug artesunate was even more active (IC50: 1.0 nM), whereas all strains were chloroquine-
resistant (IC50: 113 nM).
Conclusion:  The peptide α',β'-epoxyketone epoxomicin is highly active against P. falciparum
regardless the grade of the parasite's chloroquine susceptibility. Therefore, inhibition of the
proteasome is a highly promising strategy to develop new antimalarials. Epoxomicin can serve as a
standard to compare new inhibitors with species-specific activity.
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Background
Treatment and control of Plasmodium falciparum infec-
tions in highly endemic regions strongly rely on chemo-
therapy [1]. However, parasite resistance to existing
antimalarials is spreading rapidly and might disseminate
to artemisinins, the current mainstay of treatment against
drug-resistant parasites in the near future. Therefore, the
development of new treatment strategies is of great impor-
tance.
The ubiquitin/proteasome system regulates the turnover
of most proteins in eukaryotic cells and hence, plays an
essential role in controlling protein quality, cell prolifera-
tion, cell death, and signal transduction. In P. falciparum
protein quality control is of particular importance
because: i) erythrocytic stage parasites have a high replica-
tion rate, ii) plasmodial proteins are large in size, iii) low
complexity regions are abundant between and within
globular domains, and iv) proteins are stressed by
increased temperature in the host (fever). Those features
are important challenges to the protein folding and degra-
dation machinery. To avoid lethal accumulation of non-
functional or misfolded proteins, protein quality needs to
be tightly controlled. Previous studies show that in plas-
modia two T1 threonine peptidase systems are present.
The 20S proteasome is enzymatically active and expressed
throughout the live cycle, whereas PfhslV is expressed in
late stages of development [2], only.
Several studies investigated a single T1 threonine pepti-
dase inhibitor (herein after referred to as proteasome
inhibitor) to show its potential as a drug development
candidate [2-5] but a comprehensive study on available
classes of inhibitors is not available. Simultaneous testing
of multiple inhibitor classes reveals the most potent
inhibitor class amongst all inhibitors tested under identi-
cal assay conditions and indicates interactions between
individual compounds. If a known antimalarial drug is
included, the potency of the inhibitor can be directly eval-
uated in relation to the activity of the comparator drug
and possible pharmacodynamic interactions can be
revealed.
So far, all studies with proteasome inhibitors were done in
laboratory isolates only. It is important to assess the activ-
ity of a drug candidate against fresh P. falciparum isolates
from the field. These parasites are genotypically and phe-
notypically different from laboratory adapted strains and
are very diverse in their genetic background. Differences in
the range of activities between laboratory and field iso-
lates cannot be predicted and a high variance in drug-
activities in field isolates can indicate natural heterogene-
ity and a propensity to develop resistance against the can-
didate.
Several classes of proteasome inhibitors have been identi-
fied and a number of inhibitors have entered clinical tri-
als. Previous studies proved proteasome inhibitors of
various classes to influence growth of P. falciparum [2-5].
Here, representatives of peptide and non-peptide proteas-
ome inhibitors classes were screened for their potency
against P. falciparum laboratory strains. The most promis-
ing agents were further investigated in fresh isolates from
malaria patients in Lambaréné, Gabon.
Materials and methods
Parasites
Screening of proteasome inhibitors were conducted with
P. falciparum strains 3D7, D10 and Dd2. Parasites were
obtained from MR4 (ATCC, USA). Subsequently, a selec-
tion of inhibitors was tested in field isolates from Gabon.
Therefore, blood samples (n = 81) of children with
uncomplicated malaria were collected at the Medical
Research Unit of the Albert Schweitzer Hospital, Lam-
baréné, Gabon. Inclusion criteria were: I) P. falciparum-
monoinfection (parasitemia between 103  and 1.2*105
parasites/μl blood), II) age between one and fifteen years,
and III) no intake of antimalarial drugs for at least one
month. A venous blood sample (0.5 ml) was drawn,
washed once with parasite culture medium and applied
immediately in the drug susceptibility assay. Informed
consent and assent were obtained from the patients and/
or their parents before collection of blood. The study was
approved by the ethics committee of the International
Foundation of the Albert Schweitzer Hospital in Lam-
baréné.
Consistency of the results over the study period was tested
by correlation analysis of admission number and IC50s
against all drugs to exclude temporal trends and degrada-
tion of study compounds (endoperoxides such as artesu-
nate are particularly prone to decomposition).
Reagents
Epoxomicin (MW: 555), YU101 (MW: 635, Calbiochem),
YU102 (MW: 501), MG132 (MW: 476), MG115 (MW:
461), Z-L3-VS (MW: 551), Ada-Ahx3-L3-VS (MW: 936) and
gliotoxin (MW: 326) were resuspended in dimethyl sul-
foxide at a stock concentration of 10 mM each. PR11
(MW: 1464) and PR39 (MW: 4721) were dissolved in ster-
ile PBS to a final concentration of 1 mM. Bortezomib (Vel-
cade®, MW: 384, Millennium) was purchased as a 9 mM
solution for intravenous injection. Lactacystin (MW: 376)
and chloroquine diphosphate (MW: 515, Sigma-Aldrich)
were prepared in double distilled water at 10 mM each.
Artesunate (MW: 384) was dissolved in 70% ethanol. The
maximum concentration of either solvent per well did not
exceed 0.0007%. Ninety-six well flat-bottomed plates
(Becton Dickinson) were pre-dosed with compounds
using the following range of test concentrations: 1.6 – 100Malaria Journal 2008, 7:187 http://www.malariajournal.com/content/7/1/187
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nmol/L for epoxomicin, 7.8 – 500 nmol/L for YU101,
MG132, and MG115, 0.2 – 10 mmol/L for YU102, lacta-
cystin, gliotoxin, and PR11, 4.1 – 3,000 nmol/L for borte-
zomib, 0.6 – 10,000 nmol/L for Z-L3-VS, 1.4 – 1,000
nmol/L for Ada-Ahx3-L3-VS, 0.02 – 1 mmol/L for PR39,
1.4 – 1,000 nmol/L for chloroquine diphosphate and 0.1
– 52 nmol/L for artesunate. Control wells were pre-dosed
with parasite culture medium only. All compounds were
purchased from Biomol if not otherwise stated.
Drug susceptibility assay
Drug susceptibility assays with laboratory parasite strains
as well as with field isolates were done according to pub-
lished standard procedures [6], with minor modifications.
Parasitaemia was adjusted to 0.05% with non-infected
O+-erythrocytes. Erythrocytes were resuspended in para-
site culture medium (RPMI 1640, 25 mM HEPES, 2 mM
L-glutamine, 50 μg/ml gentamicin, and 0.5% albumax) to
a hematocrit of 1.5%. Two hundred microlitres of blood-
medium-mixture were added to each well of the pre-
dosed 96-well test plates. The plates were incubated for 72
hours at 37°C in a candle jar. To assess successful in vitro
growth of field isolates, a thick blood smear of one con-
trol-well (untreated) was done after 26 hours and a simi-
lar sample was frozen at the same time to calculate
background histidine rich protein-2 (HRP2)-production.
Parasite culture was judged successful when at least 20%
parasites matured to schizonts at the 26 hours time point.
After 72 hours plates were freeze-thawed twice. Parasite
growth, calculated from HRP2-levels, was measured with
a commercially available enzyme linked immunosorbent
assay (Malaria Ag CELISA, Cellabs, Australia), according
to the manufacturers' specifications.
Number of field isolates tested per drug depended on
inhibitory concentration immediately calculated after
accomplishment of drug susceptibility assay. Highly
active drugs (50% inhibitory concentration [IC50] < 100
nM) were tested at least 20 times and drugs with modest
activity (IC50 > 100 nM) 10 times or more.
Parasite growth in erythrocyte pre-incubated with 
proteasome inhibitors
Red blood cells were resuspended in parasite culture
medium to a hematocrit of 5% and incubated for three
hours in 37°C with proteasome inhibitors at a concentra-
tion well above their respective IC99: epoxomicin (50.0
nM), YU101 (0.5 μM), MG132 (5.0 μM), MG115 (0.5
μM), Z-L3-VS (1.0 μM) and Ada-Ahx3-L3-VS (50.0 nM).
After extensive washings pre-treated erythrocytes were
used for culture with ring stages of 3D7 and Dd2. Parasite
culture and assessment of growth was determined as it is
described above. Untreated erythrocytes served as control
for growth. All experiments were done in triplicates.
Statistical analysis
Inhibitory concentrations were determined by non-linear
regression analysis of log-dose-response curves using R
v2.3.1. (The R Foundation for Statistical Computing).
Median IC50, 90 and 99 were calculated. Correlations
between proteasome inhibitors and chloroquine were
assessed by Pearson correlation coefficient (r) of logarith-
mically transformed IC50 values. Level of significance was
set at both-sided p = 0.05 for all tests. All other statistical
analysis was done with JMP v5.0.1.2 (SAS Institute).
Results
Peptide proteasome inhibitors, a β-lactone and a group of
allosterically acting inhibitors were screened for their in
vitro activity against P. falciparum strains 3D7 and D10
(both CQ-susceptible), and against Dd2 (CQ-resistant).
Subsequently, a selection of inhibitors was tested in field
isolates from Gabon.
Peptide proteasome inhibitors are small molecules based
on a short oligopeptide with a carboxy-terminal reactive
group, such as α',β'-epoxyketone, aldehyde, vinyl sulfone
or boronic acid (Figure 1). The short peptide sequence is
mediating proteasome subunit specificity and the phar-
macophore covalently binds reversible (aldehyde,
boronic acid) or irreversible (epoxyketones, vinyl sulfone)
to the active site amino-terminal threonine of the protea-
some subunits. Clasto-lactocystin  β-lactone, the active
intermediate of lactacystin, is a cyclic compound and irre-
versibly inhibits proteasome function via an ester bond-
ing. Gliotoxin and the proline and arginine-rich peptides
PR39 and PR11, respectively, are structurally different and
all inhibit the proteasome by allosteric binding [7,8].
Screening of proteasome inhibitors against P. falciparum 
laboratory strains
Inhibitory concentrations of artesunate and chloroquine
were determined in 3D7, D10 and Dd2 and served as a
benchmark for activity and non-activity, respectively.
Amongst the peptide α',β'-epoxyketone inhibitors the
antiparasitic potency of epoxomicin and its synthetic ana-
logue YU101 is very high (Table 1). Only epoxomicin is in
the range of artesunate's antiparasitic activity. YU102,
demonstrating a high value for inhibition of the caspase-
like activity compared to YU101, did not block growth of
any parasite strain tested.
Though both peptide aldehydes MG132 and MG115 are
less active than epoxomicin, MG132 shows an inhibitory
profile in the lower nanomolar range and is superior over
MG115 in both CQ-susceptible and CQ-resistant para-
sites.Malaria Journal 2008, 7:187 http://www.malariajournal.com/content/7/1/187
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Chemical structure of proteasome inhibitors Figure 1
Chemical structure of proteasome inhibitors. Pharmacophores are shown in red. PR39 and PR11: amino acid sequence 
is shown; binding sites are so far unknown.
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The tested inhibitors of the peptide vinyl sulfone class
show a wide range of activities. Whereas the potency of Z-
L3-VS is in the low nanomolar range, the inhibitory con-
centration of Ada-Ahx3-L3-VS is 19 times higher in 3D7
and 42 times in Dd2. Bortezomib, a peptide boronate, is
the only proteasome inhibitor in clinical use so far. In
contrast to multiple myeloma treatment [9], its activity in
P. falciparum laboratory strains was low. The non-peptide
based inhibitor lactacystin did not demonstrate inhibi-
tion of parasites' growth at low concentration. Amongst
the group of allosterical inhibitors, gliotoxin demon-
strated some modest activity whereas no inhibition was
detectable for the peptide antibiotic PR39 and its deriva-
tive PR11 in the concentration range tested.
Growth of 3D7 and Dd2 in pre-treated erythrocytes
To exclude growth inhibition of parasites due to inhibited
host cell proteasomes uninfected erythrocytes were incu-
bated with epoxomicin, YU101, MG132, MG115, Z-L3-VS
and Ada-Ahx3-L3-VS, respectively. Pre-treated red blood
cells were used for cultivation of 3D7 and Dd2. No growth
inhibition was observed after 72 hours.
In vitro activity of selected proteasome inhibitors in P. 
falciparum field isolates from Gabon
Based on the screening in laboratory strains of P. falci-
parum the following proteasome inhibitors were selected
for testing in fresh isolates obtained from malaria patients
from Lambaréné, Gabon: the most effective peptide α',β'-
epoxyketone inhibitor epoxomicin and MG132. Even
though bortezomib and lactacystin showed only minor
antimalarial activity in laboratory strains, they were cho-
sen. Bortezomib is the only proteasome inhibitor which is
in use in humans. Lactacystin has been thoroughly tested
in P. falciparum in previous studies and served as a bench-
mark for antiplasmodial activity of proteasome inhibitors
tested in this study. Testing of YU101 and Z-L3-VS was
abandoned because of difficulties in compound availabil-
ity during study conduct.
In vitro drug susceptibility was tested in 22 (epoxomicin
and MG132) and 11 isolates (bortezomib and lactacys-
tin), respectively. All isolates were chloroquine resistant
whereas artesunate was highly active (Table 2). Epox-
omicin showed the highest molecular activity with a range
of activities in individual samples that were remarkably
narrow (Figure 2). Potency of MG132 proved to be as high
as in laboratory strains. Activity of bortezomib and lacta-
cystin in field isolates was very low with a wide range of
activity in the individual samples. No proteasome inhibi-
tor showed any significant cross correlations neither with
chloroquine- nor with artesunate-activities.
Discussion
In view of increasing levels of P. falciparum resistance to
antimalarial drugs currently in use, there is an urgent need
to develop new treatment strategies. Proteasome inhibi-
tors are in the focus of drug development for various dis-
eases and candidates have already entered clinical trials
[10]. In plasmodia several studies show the potential of a
single proteasome inhibitor as a drug development candi-
date [2-5]. Even though different growth detection meth-
ods give highly comparable results, assay parameters,
mainly the initial parasitaemia used in the drug suscepti-
bility assay, affects IC50 values [11]. Thus comparison of
inhibitor activities between different studies is problem-
atic, particularly if no comparator drug is tested in paral-
lel. Here, the first comprehensive study on proteasome
inhibitors against P. falciparum is provided. The most
promising inhibitor amongst all classes tested was identi-
fied and its activities were compared with artesunate, one
of the most active antimalarial compounds known. More-
over, differences in activities between the inhibitor classes
are not biased by assay parameters because all com-
pounds were tested in parallel and under exactly the same
assay conditions.
Table 1: Screening of 50% inhibitory concentrations of 
proteasome inhibitors in P. falciparum laboratory strains 3D7, 
D10 and Dd2
IC50 (nmol/L)a
Test compounds 3D7 D10 Dd2
1. Peptide proteasome inhibitors
Epoxomicin 6.8 1.7 10.4
YU101 24.5 17.0 13.8
YU102 1740 4000 3006
MG115 97.5 50.0 44.9
MG132 22.4 33.2 17.3
Z-L3-VS 16.4 n.d. 4.9
Ada-Ahx3-L3-VS 300 n.d. 210
Bortezomib 252 127 561
2. β-lactone
Lactacystin 1490 1211 2553
3. Allosteric inhibitors
Gliotoxin 2171 n.d. 1165
PR11 n.i. n.d. n.i.
PR39 n.i. n.d. n.i.
4. Comparator drugs
Artesunate 0.5 2.5 0.9
Chloroquine 8.3 5.0 176
a Values are expressed as mean IC50 from two separate 
determinations against chloroquine-susceptible 3D7 and D10 and 
chloroquine-resistant Dd2 clones.
n.d. assay not done
n.i. no growth inhibition detectableMalaria Journal 2008, 7:187 http://www.malariajournal.com/content/7/1/187
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The knowledge of activity of antimalarial drug candidates
against field isolates is critical to estimate their potential
in the drug development process. Freshly isolated para-
sites are heterogeneous in their genetic background and
represent the local plasmodial population, including pre-
existing mutations that account for drug resistance,
whereas laboratory isolates are oligo- or monoclonal and
are heavily selected for in vitro growth. It is important to
establish the variability of efficacy of antimalarials (as it is
seen in the range of IC50 values) against parasites with a
diverse genetic background. The discrepancies seen
between assays carried out on (fresh) patient isolates and
on laboratory adapted strains cannot be predicted. Borte-
zomib showed a remarkably lower activity against P. falci-
parum field isolates then it was seen in laboratory strains.
Furthermore, the variability in susceptibilities of patient
isolates to one proteasome inhibitor class can be com-
pared to the variability of susceptibilities to another com-
pound. These comparisons can point to potential
mechanisms of drug action as well as drug resistance.
Resistance against chloroquine is highly prevalent in the
study area and exclusion of cross-resistance with chloro-
quine is of major concern.
Peptide a',β'-epoxyketones are the most potent and spe-
cific proteasomal inhibitor class in mammalian cells so far
[12]. In P. falciparum the peptide epoxyketone epox-
omicin, an actinomycetes metabolite, showed the highest
antimalarial activity in laboratory strains as well as in field
isolates, independent of the chloroquine-susceptibility of
Distribution of individual 50% inhibitory concentrations Figure 2
Distribution of individual 50% inhibitory concentrations. Distribution of single IC50s of artesunate (A), chloroquine 
(CQ), epoxomicin (Ep), MG132 (MG), bortezomib (B) and lactacystin (L) in P. falciparum field isolates. Outlier box plots show 
median IC50 and ends of the box are the 25% and 75% quantiles, respectively. The whiskers extend from the ends of the box 
to the outermost data point that falls within the distances computed. Dots outside whiskers are possible outlier IC50s. Note: 
concentration (nM) is shown in logarithmic scale.
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the parasites. The narrow range of activity in the individ-
ual samples argues for a low potential of resistance-devel-
opment. Interestingly, caspase-like subunit specific
YU102 [13] did not affect parasite growth, whereas
YU101 [14], a chymotrypsin-like specific inhibitor, inhib-
ited parasites in the low nanomolar range. YU101 and
YU102 are synthetic derivates and their peptide modifica-
tions were designed to target only one proteasomal prote-
olytic subunit with a high degree of specificity and
potency. Even though epoxomicin is not specific for the
plasmodial proteasome, YU-compounds show that it is
principally possible to design epoxyketones towards sub-
unit specific inhibition. If more is known about plasmo-
dial proteasome particularities, like their low complexity
regions in their active subunits [2], engineering of plas-
modia specific epoxyketones should be feasible. The pep-
tide vinyl sulfone analogue of MG132, Z-L3-VS, was
considerable more potent in P. falciparum then Ada-Ahx3-
L3-VS, a vinyl sulfone with an amino-terminal extension.
This was surprising because in mammalian proteasomes
the extended peptide vinyl sulfones were shown to be
superior in potency over their shorter counterparts [15].
Presumably, the amino-terminal extension of Ada-Ahx3-
L3-VS is hampering the molecule's permeability to the
three membranes of P. falciparum infected erythrocytes.
Although MG132 showed promising antimalarial activity
regardless of the chloroquine susceptibility of the para-
sites, a major drawback of peptide aldehydes is their lack
of proteasomal specificity. The proline and arginine-rich
peptides PR39 and PR11 regulate the proteasome activity
in a substrate-specific manner. They are unique in that
they bind allosterically to the α subunits of the proteas-
ome and change the shape of the proteasome. Only the
degradation of a small subset of proteins is affected and
thus antimicrobial peptides are less toxic than conven-
tional competitive proteasome inhibitors [8]. In plasmo-
dia no activity could be observed, however, inhibition of
purified plasmodial proteasomes was not investigated.
Although lactacystin and gliotoxin have already been
shown active against P. falciparum [3,5], in the light of
other proteasome inhibitor classes and comparator drugs
their activity was of minor significance.
Currently, proteasome inhibitors are intensely investi-
gated for their antimicrobial activity by several academic
groups and companies. We hope to set a standard for pre-
clinical in vitro studies of antimalarial inhibitors and look
forward to the further development of lead compounds
into clinical trials.
Conclusion
Epoxomicin is highly active against P. falciparum and
shows no signs of cross-resistance with the comparator
drugs or any other proteasome inhibitor in an area with
high-grade chloroquine resistance. Epoxomicin is a
benchmark for the development of highly active, species-
specific proteasome inhibitors. Additionally, epoxomicin
is a valuable tool in plasmodial proteasome investiga-
tions.
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